0.481438
Relative Brier Score
9
Forecasts
0
Upvotes
Forecasting Calendar
| Past Week | Past Month | Past Year | This Season | All Time | |
|---|---|---|---|---|---|
| Forecasts | 0 | 0 | 9 | 9 | 9 |
| Comments | 0 | 0 | 6 | 6 | 6 |
| Questions Forecasted | 0 | 0 | 6 | 6 | 6 |
| Upvotes on Comments By This User | 0 | 0 | 0 | 0 | 0 |
| Definitions | |||||
Why do you think you're right?
Argentina has a very recent history of defaults (2001, 2014, and 2020) and currently holds an external debt close to half of GDP, with limited international reserves and significant political instability. This strongly increases the probability of another default.
Bolivia, although it has not defaulted since the 1980s, is now under pressure due to persistent fiscal deficits, declining international reserves, and heavy reliance on gas exports amid uncertain global prices. These conditions raise risks, even though Bolivia has historically prioritized debt repayment.
Ecuador defaulted recently in 2020 and remains highly vulnerable to oil price fluctuations and external shocks. With external debt above 50% of GDP and ongoing fiscal weaknesses, the risk of another default is moderate to high.
Overall, the combination of macroeconomic fundamentals, debt sustainability concerns, and political risk justifies the probabilities assigned.
Why might you be wrong?
Several factors could lower the actual risk of default. First, governments may negotiate refinancing or restructuring agreements with the IMF, World Bank, or private creditors, which would ease near-term debt service. Second, unexpected improvements in commodity prices (oil, gas, soy, minerals) could boost fiscal revenues and foreign reserves. Third, political changes could bring about fiscal reforms or new multilateral support.
In particular, Bolivia could secure bridge financing from strategic partners such as China, CAF, or the IDB. Argentina could rely on additional IMF disbursements or stricter capital controls to stabilize reserves. Ecuador could gain breathing room if fiscal discipline is maintained and oil prices recover.
In short, while risks remain high, shifts in international conditions or domestic policy could lead to outcomes that differ from the forecast.
Why do you think you're right?
Germany’s net perception of Ukraine has shown a consistent trend: +8 (2021–22), +32 (2023, peak solidarity), and +27 (2024, start of fatigue). The 5-point drop between 2023 and 2024 suggests a gradual erosion in public support due to war fatigue, economic costs, political polarization, and Russian disinformation. I expect this trend to continue moderately, leaving Germany’s net perception in the +20 to +25 range in 2026.
Why might you be wrong?
I could be wrong if unexpected shocks occur. For example, a major Ukrainian success in late 2025 or a strong German/EU political campaign could reverse the downward trend, pushing the score back above +30. Conversely, a dramatic surge in AfD support, severe economic downturn, or a visible Ukrainian setback could accelerate the decline, dropping perceptions closer to +15.
Why do you think you're right?
Based on the current political dynamics, I believe the most likely resolution is "Not before 2026", meaning no bilateral ceasefire or peace agreement will take effect before January 1, 2026. Despite multiple attempts at negotiations—including the most recent talks in Saudi Arabia and the U.S. proposal for a 30-day ceasefire—there are still deep-rooted issues unresolved: territorial claims, NATO security concerns, and the increasing geopolitical involvement of external powers like the U.S. and China. While Russia’s tentative support for a ceasefire might seem promising, its insistence on “outstanding questions” and Ukraine’s prior rejection of U.S.-linked terms suggests meaningful consensus is still elusive.
Why might you be wrong?
I might be wrong if the humanitarian toll, economic fatigue, and pressure from international actors converge rapidly enough to force a short-term bilateral ceasefire—perhaps one symbolically timed with a major diplomatic event or seasonal milestone (e.g., UN General Assembly or winter energy crisis). In such a scenario, even a temporary but formal ceasefire could unexpectedly take effect in late 2025.
Why do you think you're right?
Mirror biology research is likely to fall under dual-use oversight by 2030 due to its potential biosecurity and biosafety risks.
Governments in the U.S., EU, and UK already have established frameworks for Dual Use Research of Concern (DURC) or equivalent mechanisms that regulate life sciences research which could be misapplied to cause harm (for instance, NIH’s DURC policy in the U.S., EU’s export control list, and UKRI oversight requirements).
As mirror organisms could theoretically evade immune systems, spread as invasive species, or resist conventional antibiotics, the risk-benefit balance will almost certainly trigger formal policy discussions.
By the late 2020s, early research on mirror bacteria or synthetic mirror life will likely mature enough to attract scrutiny from bioethics and national security agencies—similar to how gain-of-function or synthetic biology research has already done.
Given the pace of policy adaptation and the increasing attention to biosecurity threats emerging from synthetic biology, it is plausible that by 2030 at least one jurisdiction (most likely the EU) will classify mirror biology under dual-use oversight. The EU has historically been faster to extend precautionary frameworks to novel biotechnologies (e.g., CRISPR, gene drives, and AI-assisted bioengineering).
Why might you be wrong?
There are three main uncertainties that could prevent classification by 2030:
Technological Immaturity:
Mirror life remains mostly theoretical. If tangible applications or lab prototypes are still a decade away, regulators may postpone oversight until the field becomes more experimentally relevant.
Scientific Disagreement:
Some experts argue that mirror life poses limited near-term risk since it cannot interact directly with natural biochemistry. Without clear evidence of hazard potential, policymakers might not prioritize new regulation.
Regulatory Lag:
Both the U.S. and UK tend to respond reactively rather than proactively to new biotechnologies. Implementation of new DURC or export control categories typically takes years of consultation and inter-agency review.